ISR Holding: Signs an agreement with Catalent Inhalation
Research Note
2022-06-29
12:56
Redeye is encouraged to learn that ISR has signed an agreement with Catalent Inhalation to scale-up its spray-dried nasal vaccine, powder formulation for its clinical phase III study.
EL
JU
Ethel Luvall
Johan Unnerus
Disclosures and disclaimers